Dr. Brett W. Sperry, MD

Medicare patients and services

Medicare patients, 2024

919

Services billed

2,154

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 7 companies reported 69 payments worth $82,823 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Missouri →

Industry-funded research

Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $191,824 in research payments for these studies, mostly to the institutions running them.

• A phase 3,radomized,double-blind,placebo-controlled,multicenter study to evaluate the efficacy and safety of amyloid depleter ALXN2220 in adult participants wiith transthyretin amyloid cardiomyopathy ATTR CM
  Alexion Pharmaceuticals, Inc.
• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
  Eidos Therapeutics, Inc. · Recruiting · NCT06563895
• A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Amyloid Transthyretin (ATTR) Amyloidosis
  AstraZeneca UK Limited
• An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
  Ionis Pharmaceuticals, Inc. · Enrolling by invitation · NCT05667493
• Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
  Eidos Therapeutics, Inc. · Active, not recruiting · NCT04988386
• CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
  Ionis Pharmaceuticals, Inc. · Completed · NCT04136171

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Heart Failure & Transplant Cardiology clinicians in Kansas City

• Bethany A. Austin, MD
• Mark P. Everley, MD
• Andrew C. Kao, MD
• Taiyeb M. Khumri, MD
• Stephanie L. Lawhorn, MD
• Michael Nassif, MD